Related Experiment Video
Updated: Jul 2, 2026
05:51
A Streamlined and Standardized Procedure for Generating High-Titer, High-Quality Adeno-Associated Virus Vectors Utilizing a Cell Factory Platform
Published on: May 3, 2024
A novel and highly efficient production system for recombinant adeno-associated virus vector
Zhijian Wu1, Xiaobing Wu, Hui Cao
1State Key Laboratory for Molecular Virology and Genetic Engineering, Institute of Virology, Chinese Academy of Preventive Medicine, 100052, Beijing, China.
Science in China. Series C, Life Sciences
|September 3, 2008
Summary
This study introduces a novel system for producing recombinant adeno-associated virus (rAAV) gene therapy vectors. The new method significantly enhances rAAV yields, potentially meeting clinical trial demands.
Area of Science:
- Molecular Biology
- Gene Therapy
- Virology
Background:
- Recombinant adeno-associated virus (rAAV) is a key vector for gene therapy.
- Current rAAV production methods face challenges in achieving high yields and titers.
- Efficient production is crucial for advancing rAAV-based clinical applications.
Purpose of the Study:
- To develop a novel and highly efficient production system for recombinant adeno-associated virus (rAAV).
- To significantly increase the yield of infectious rAAV vectors for gene therapy applications.
Main Methods:
- Construction of a recombinant herpes simplex virus type 1 (rHSV-1) expressing AAV-2 Rep and Cap proteins (HSV1-rc/DeltaUL2).
- Establishment of an rAAV proviral cell line (BHK/SG2) containing a green fluorescent protein (GFP) gene cassette.
- Infection of the BHK/SG2 cell line with HSV1-rc/DeltaUL2 at a multiplicity of infection (MOI) of 0.1.
Main Results:
- The rHSV-1 helper virus successfully supported rAAV replication and packaging.
- Optimal rAAV yields of 250 transducing units (TU) or 4.28x10^4 particles per cell were achieved.
- This novel strategy increased rAAV yield by two orders of magnitude compared to conventional methods.
Conclusions:
- The developed "one proviral cell line, one helper virus" strategy offers a highly efficient method for rAAV production.
- This system can achieve large-scale production of rAAV, potentially fulfilling clinical trial requirements.
- The enhanced yield facilitates the advancement of rAAV-mediated gene therapy.
